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We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal
adenocarcinoma. In phase I, doses were escalated in chemotherapy naı ¨ve or pretreated patients to establish maximum tolerated
doses (MTD). In phase II, patients were treated at MTD as first-line therapy with the primary end point of RECIST response. Dose
levels in phase I were as follows: Level 1: irinotecan 150mgm
 2 on day 1; capecitabine 850mgm
 2 12-hourly on days 1–9. Level 2:
as level 1 but capecitabine 1000mgm
 2. Level 3: as level 2 but irinotecan 180mgm
 2. Level 4: as level 3 but capecitabine
1250mgm
 2.I nphase I, 21 patients were entered. Maximum tolerated dose was level 3. Dose-limiting toxicities were lethargy,
diarrhoea, vomiting and mucositis. In phase II, 31 patients were entered at level 3. During the first six cycles, 13 of these patients
underwent dose reduction and three patients stopped treatment for toxicity. A further six patients stopped for progressive disease.
The commonest grade 3–4 toxicities were lethargy (20%), diarrhoea (17%), nausea (10%) and anorexia (10%). There were no
treatment-related deaths. The response rate was 32% (95% CI 16–52%). Median overall survival was 10 months. This regimen is
active in gastroesophageal adenocarcinoma. However, using the MTD defined in phase I, fewer than 50% patients tolerated six cycles
without modification in phase II; therefore, modification of these doses is recommended for further study.
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Gastroesophageal cancer is one of the commonest malignancies
worldwide, with around 1.5 million new cases diagnosed in 2002.
In the same year, it accounted for over a million deaths, second
only to lung cancer (Globocan, 2002). The incidence of adeno-
carcinoma of the gastroesophageal junction as well as the
surrounding distal oesophagus and proximal stomach is rising
rapidly in the western world, particularly in younger (40–70 years)
white males (Brown and Devesa, 2002). Palliative chemotherapy
for locally advanced or metastatic disease prolongs survival and
improves quality of life over best supportive care (Murad et al,
1993). However, responses tend to be of short duration and
median survival is generally less than 1 year. There is no
international gold standard regimen, but ECF (epirubicin;
cisplatin; protracted infusional 5-fluorouracil (FU)) is accepted
as a reference regimen in the UK and Europe, having proven
superior to a previous standard regimen, FAMTX (FU, adriamycin
and methotrexate) in a phase III randomised trial (Webb et al,
1997). More recently, this regimen has been demonstrated to
improve long-term survival when added to surgery for operable
disease (Cunningham et al, 2005). Thus, chemotherapy is
becoming increasingly important in the management of this
disease at all stages.
However, the ECF regimen is burdensome to the patient, usually
entailing an overnight hospital stay, a central line and ambulatory
pump for drug delivery, all impacting upon patients’ quality of life.
Cisplatin is nephro- and neurotoxic and may cause significant
asthenia, whereas epirubicin, which makes an uncertain contribu-
tion to the regimen, is associated with alopecia, mucositis and
cardiotoxicity. The investigation of alternative chemotherapeutic
regimens is therefore desirable.
Irinotecan causes DNA damage through interaction with
toposoimerase I, and is active in a number of malignancies. In
colorectal cancer, it forms part of standard first-line therapy for
metastatic disease, where its optimum use, both in terms of activity
and toxicity, appears to be fortnightly in combination with
infusional FU and leucovorin (LV) (Douillard et al, 2000;
Tournigand et al, 2004; Seymour, 2005). In advanced gastro-
esophageal cancer, irinotecan has been studied in phase II trials as
a single agent and in combination with various other agents,
including FU and cisplatin. Single-agent response rates are around
20%, although rates of up to 60% have been reported for irinotecan
combined with cisplatin (Kohne et al, 2003; Wohrer et al, 2004).
Capecitabine is an orally bioavailable FU prodrug, which offers
effective fluoropyrimidine therapy while avoiding prolonged
intravenous infusion. The final step in its conversion to FU is
catalysed by thymidine phosphorylase, an enzyme that is over-
expressed in gastric cancers (Miwa et al, 1998), which could
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spotentially offer a therapeutic index advantage for capecitabine
over FU. The drug is widely used in colorectal cancer where it has
proven at least equivalent efficacy but a favourable toxicity profile
when compared to bolus intravenous FU/LV in randomised phase
III studies (Van Cutsem et al, 2004; Twelves et al, 2005). It also
appears active in gastroesophageal adenocarcinoma. Phase II
studies of capecitabine given as a single agent or in combination
with a variety of other active agents have been carried out and
produced promising response rates (Hong et al, 2004; Lorenzen
et al, 2005). Preliminary data from the randomised ‘REAL 2’ trial
in this disease show that capecitabine can be substituted for
infusional FU as part of the ECF regimen without loss of efficacy
(Sumpter et al, 2005). Preclinical data suggest that capecitabine
and irinotecan may act synergistically (Hapke et al, 2001).
Thus, there is good reason to investigate the combination of
irinotecan and capecitabine in the management of gastroesopha-
geal adenocarcinoma. However, the optimum schedule for this
combination has not yet been established. Studies in colorectal
cancer have most commonly been based on the standard single-
agent capecitabine schedule of 14 days treatment every 3 weeks,
with irinotecan added as a single 3-weekly administration.
However, the tolerability of this regimen is uncertain (Kohne
et al, 2005). We therefore decided that, while evaluating these
drugs in gastroesophageal cancer patients, we would take the
opportunity to explore a different schedule, modelled on the
attractive 2-weekly FOLFIRI regimen now well established in
colorectal cancer. Capecitabine was administered on days 1–9 of
the 14-day cycle in order to maintain dose density comparable
with standard capecitabine schedules. The aims of this phase I/II
study were to define the optimum doses of the combination and to
obtain preliminary efficacy data.
PATIENTS AND METHODS
The study included phase I and phase II components. Phase I was
open to chemo-naı ¨ve or pretreated patients, and incorporated both
between-cohort and within-cohort dose escalation in order to
establish optimum doses of both drugs. In phase II, these doses
were evaluated for efficacy and tolerability, over a 12-week
treatment period, in a further 31 patients receiving the regimen
as first-line treatment for advanced disease.
Recruitment to the phase I component of the study was from a
single institution and started in September 2001. Two further
centres were involved in recruitment to the phase II component,
which completed in November 2002. Ethical approval was obtained
at all participating institutions. To be eligible for either phase,
patients had to have histologically confirmed locally advanced or
metastatic adenocarcinoma of the oesophagus or stomach,
unsuitable for curative surgery or chemoradiotherapy; age
418years; WHO performance status 0, 1 or 2; adequate
haematological and biochemical parameters (white blood cells
X4, platelets X150, bilirubin p1.5 upper limit of normal
(ULN), alkaline phosphatase o5 ULN, aspartate aminotransfer-
ase and alanine aminotransferase o2.5 ULN and creatinine
clearance 450mlmin
 1); and written, informed consent. Main
exclusion criteria were as follows: prior radical chemoradio-
therapy; treatment with radiotherapy or any investigational drug
within the preceding 4 weeks; a prior severe reaction to
fluoropyrimidine therapy; concurrent uncontrolled medical con-
dition (e.g. angina and cardiac failure), infection or diarrhoea;
requirement for a contraindicated medication; history of epilepsy;
any condition that may impair oral self-medication; pregnant or
lactating women, or inadequate contraception in women of
childbearing potential.
In addition to these general selection criteria, patients in
the phase II study were required to have measurable disease,
and may not have received prior palliative chemotherapy for
locally advanced/metastatic disease. Prior (neo)adjuvant, chemo-
therapy was allowed if completed at least 3 months before
randomisation.
Pretreatment evaluation and study assessments
Clinical evaluation and investigations to confirm eligibility were to
be completed within 1 week before starting therapy. Investigations
to measure disease, such as endoscopy, computed tomography
(CT) and/or magnetic resonance imaging, were required within 3
weeks. On the first day of each treatment cycle, patients were
evaluated for toxicity using the NCIC-CTC version 2 and blood was
drawn for full blood count (FBC), renal and liver function.
Response to treatment was formally assessed following cycle 6
(weeks 13–14). Standard RECIST criteria were used to define a
partial or complete response, stable disease or disease progression.
Responses required confirmation with repeat assessment at least 4
weeks later.
Treatment of patients
Irinotecan was administered at doses ranging from 150 to
180mgm
 2 in 250ml normal saline over 1h. Capecitabine was
administered at doses ranging from 850 to 1250mgm
 2 (to the
nearest dose achievable using 500 and 150mg tablets). The first
dose was taken at the end of the irinotecan infusion, the second at
2100 the same evening, and thereafter at 0900 and 2100, within
30min of ingestion of food, on days 1–9 (total 18 doses). Cycles
were repeated every 14 days. Conventional supportive measures
for nausea/vomiting, anticholinergic syndrome and diarrhoea were
employed. Protocol-specified standard dose reductions and/or
delays were implemented based on toxicity experienced during the
previous cycle and pretreatment haematological, renal and
hepatobiliary function.
Table 1 shows the four dose levels tested in the dose-escalation
phase. At each dose level, patients were recruited until at least four
had completed at least three cycles of treatment, but without
pauses (so total cohort size could exceed four patients). Recruit-
ment then progressed to the next dose level if 25% or less of four
or more patients had experienced a dose-limiting toxicity (DLT)
during the first three cycles. In addition, patients who were entered
at dose levels 1 or 2 who experienced no toxicity above grade 2
after the first three cycles could be escalated to the next dose level
and contribute to the evaluation of that dose. Dose-limiting
toxicity was defined as any non-haematological toxicity (excluding
alopecia) of grade X3, or haematological toxicity of grade 4
causing a chemotherapy delay of more than 5 days. Maximum
tolerated dose (MTD) was defined as one dose level below that
causing DLT in 425% of four or more patients. This was the dose
taken forward to the phase II component of the study.
Study treatment was planned to last 12 weeks (six cycles) at
which time the primary efficacy end point of response rate was
assessed. Patients who had stable or responding disease at this
time could, at the investigators discretion, then continue on the
same regimen, either immediately or after a break. Any treatment
Table 1 Dose-escalation schedule
Level
Irinotecan dose (1h i.v.
infusion, day 1)
(mgm
 2)
Capecitabine dose
(p.o., every 12h, days
1–9) (mgm
 2)
1 150 850
2 150 1000
3 180 1000
4 180 1250
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sbeyond six cycles, however, did not contribute to efficacy
assessment. Patients could also be considered, at this time, for
surgery or radiotherapy if appropriate. Study treatment was
discontinued in the event of disease progression during chemo-
therapy, intolerable adverse events or at the patient’s request.
Second-line therapy with ECF was available when appropriate.
Statistical considerations
It was planned to recruit 30 patients to the phase II study. This
sample size provides a reasonable estimate of the response rate
upon which to base further study design. For example, 15 (50%)
responders would give a true response rate estimate of 31–69%
(a1¼2.5%; a2¼5%; g¼95% binomial sampling distribution;
Neave, 1981). An early stopping rule would have closed the study
after 14 patients if no RECIST responses had been seen as this
would indicate a 95% probability of the true response rate being
o20%.
Overall survival was calculated from the date of first
chemotherapy administration to the date of last follow-up or
death from any cause. Median overall survival was estimated using
the Kaplan–Meier method.
RESULTS
Twenty-one patients were recruited to the phase I dose-escalation
study and 31 to the phase II study. Table 2 summarises their
pretreatment characteristics. The majority were male, had good
performance status and had the primary tumour in situ. Half were
symptomatic. The median age for the combined cohorts was 61
years. The vast majority were chemotherapy naı ¨ve. Three patients
in phase I had received prior palliative chemotherapy and one had
received prior preoperative chemoradiotherapy. One patient in
phase II had previously received neoadjuvant chemotherapy.
Phase I
Table 3 summarises the DLTs experienced.
Five patients were recruited to dose level 1. Dose-limiting
toxicity occurred in one patient (grade 3 lethargy) after the first
cycle, who declined further treatment. Two other patients tolerated
three cycles but came off study at that point, one because of
progressive disease and the other died as a result of chronic
obstructive airways disease, unrelated to treatment. The other two
patients were escalated to dose level 2, one of whom died from a
cerebrovasular accident, not attributed to chemotherapy, after one
further cycle.
Six patients were entered at dose level 2. One developed DLT
(grade 3 mucositis and diarrhoea) and discontinued treatment
after two cycles. The other five patients all completed at least three
cycles and three were escalated to dose level 3. Two patients
required a non-DLT-related dose reduction or delay, hence were
not escalated. No DLTs occurred in the six patients either entered
at, or escalated to, dose level 3, all of whom completed at least
three cycles at the intended dose. At dose level 4, six out of seven
patients experienced a DLT (Table 3) and all seven required a dose
reduction.
Dose level 3 was therefore declared the MTD and patients
recruited to the phase II study were treated at this dose. No
haematological DLTs were encountered at any dose level.
Phase II
Toxicity Thirty-one patients were entered into the phase II study,
but one patient had disease progression and died before receiving
any study therapy. A total of 165 cycles were administered to the
remaining 30 patients of which 117 (71%) were at the full dose.
Table 2 Patient characteristics (number (%))
Phase I Phase II Total
N¼21 N¼31 N¼52
Median age (range) 57 (40–71) 63 (40–78) 61 (40–78)
Gender
Male 18 24 42
Female 3 7 10
WHO performance status
0 7 (33) 10 (32) 17 (33)
1 14 (66) 16 (52) 30 (57)
2 0 5 (16) 5 (10)
Symptomatic 12 (57) 15 (48) 27 (51)
Primary tumour site
Stomach 8 (38) 18 (58) 26 (50)
OG junction 4 (19) 7 (23) 11 (21)
Oesophagus 9 (43) 6 (19) 15 (29)
Primary tumour resected 3 (14) 6 (19) 9 (17)
Measurable disease 16 (76) 31 (100) —
Sites of metastases
Local/anastomotic 0 9 (29) 9 (17)
Liver 9 (43) 14 (45) 23 (44)
Peritoneum 5 (24) 15 (48) 19 (37)
Lung 3 (14) 1 (3) 4 (8)
Lymph nodes 8 (38) 14 (35) 19 (37)
Other 3 (14) 8 (26) 11 (21)
OG¼oesophageal-gastric junction.
Table 3 DLTs experienced at four dose levels during the dose-escalation phase
Dose level 1 2 3 4
Irinotecan (mgm
 2)/capecitabine(mgm
 2 b.d.) 150/850 150/1000 180/1000 180/1250
Patients entered at dose level (n) 5 637
Patients escalated from previous dose level (n)— 2 3 —
Total patients treated (n) 5 867
Number completing at least three cycles at intended dose 4 6 6 5
DLTs (n (%))
Lethargy grade 3 1 (20) 3 (43)
Diarrhoea grade 3 1 (17) 1 (14)
Diarrhoea grade 4 1 (14)
Mucositis grade 3 1 (17)
Vomiting grade 3 1 (14)
b.d.¼twice daily; DLT¼dose-limiting toxicity.
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sPatients received a median of six cycles (range 0–12). Chemo-
therapy was delayed in 22 (13%) of cycles. The majority of
patients, 19 (63%), completed at least six cycles but of these eight
(42%) required a dose reduction. Hence, 11 patients (33%)
completed six cycles at the full dose whereas the vast majority
(86%) received two cycles and 74% received three cycles at full
dose. During the first six cycles, 13 patients required a dose
reduction, a further three stopped therapy owing to toxicity, six
withdrew owing to progressive disease and a further two patients
died. One of these two patients had a fatal pulmonary embolus and
the other died of disease progression. There were no treatment-
related deaths.
Table 4 summarises the toxicity experience per patient and
Table 5 shows the distribution of the worst toxicity grades
experienced.
Forty-two per cent of the phase II cohort experienced grade X3
toxicity at some stage during their treatment. The commonest
grade 3 toxicities were lethargy (19%), diarrhoea (16%), nausea
(10%) and anorexia (10%). Haematological toxicity was low. One
patient developed grade 4 neutropenia in association with grade 3
diarrhoea, but no neutropenic fever/infection was encountered.
Efficacy Table 6 summarises the efficacy results. Of the 31
patients recruited, three were not assessable for response: one
patient progressed before receiving any treatment and two
withdrew after only one cycle of chemotherapy owing to toxicity.
Nine (32%) of the 28 assessable patients had RECIST partial
responses and an additional nine patients (32%) achieved stable
disease for at least 12 weeks. If the non-assessable patients are
included for an ‘intent to treat’ analysis, these rates fall to 29%
partial responses and 29% stable disease. The median overall
survival for the phase II cohort was 10 months. Six of the 16 (38%)
assessable patients recruited to the phase I study responded,
including one complete response.
DISCUSSION
The combination of irinotecan and capecitabine is a reasonable
regimen to explore in advanced gastroesophageal cancer:
both drugs are known to be active; there is preclinical evidence
of synergy between them (Hapke et al, 2001); their toxicities
only partially overlap, and the regimen avoids central lines and
infusion pumps. In addition, there does not appear to be any
significant pharmacokinetic interaction between the two drugs
(Tewes et al, 2003). There are several published phase I and II
studies exploring this combination in advanced colorectal cancer
but little published data in gastroesophageal cancer. The
investigation of a 2-weekly regimen is warranted. In metastatic
colorectal cancer, 2-weekly irinotecan and infusional FU has been
extensively investigated and is a well-established regimen based on
its favourable efficacy and toxicity profile (Douillard et al, 2000;
Tournigand et al, 2004). In a large randomised trial, again in
colorectal cancer, when used as second-line therapy, 2-weekly
irinotecan/infusional FU was associated with significantly less
diarrhoea and alopecia compared with 3-weekly single-agent
irinotecan (Seymour, 2005). Moreover, a 3-weekly irinotecan/
capecitabine schedule was associated with significant toxicity in a
recent randomised study from the EORTC (Kohne et al, 2005). Our
2-weekly schedule was designed to achieve similar dose intensities
to the 3-weekly schedule investigated in colorectal cancer. (Borner
et al, 2005; Kohne et al, 2005).
The phase I component of our study established dose level 3
(irinotecan 180mgm
 2 with capecitabine 1000mgm
 2 b.d. on
days 1–9) as the MTD. None of the six patients treated at this dose
experienced a DLT, whereas six out of seven patients treated at
dose level 4 experienced DLT, principally diarrhoea, lethargy and
vomiting. We observed little haematological toxicity and no cases
of febrile neutropenia, but routine mid-cycle FBC was not
performed. Hand–foot syndrome (HFS) above grade 2 was not
encountered in our phase I cohort. By comparison, in phase I
studies of this combination in colorectal cancer, using a 3-week
cycle, the principal toxicities were diarrhoea, lethargy and
vomiting, but also neutropenia (Tewes et al, 2003; Delord et al,
2005; Rea et al, 2005).
Dose level 3 was used in the first-line setting to treat an
additional cohort of patients in the phase II study. Although 74%
of these patients were able to receive at least three cycles at the full
dose, toxicity was nonetheless significant and greater than
experienced during phase I, with 16 out of 30 (53%) patients
Table 6 Efficacy results (response rate) by phase I and II cohorts and for all assessable patients combined (n (%) (95% confidence interval))
Phase I Phase II All patients
Complete/partial response 6 (38) (15–65) 9 (32) (16–52) 15 (34) (20–50)
Stable disease 5 (31) (11–58) 9 (32) (16–52) 14 (32) (19–48)
Progressive disease 5 (31) (11–58) 10 (36) (19–56) 15 (34) (20–50)
Number of assessable patients 16 28 44
Table 4 Maximum toxicity grade per patient (number (%); n¼30)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Anaemia — 1 (3) — —
Neutropenia — 1 (3) 2 (7) 1 (3)
Lethargy 7 (23) 11 (37) 6 (20) —
Diarrhoea 10 (33) 6 (20) 5 (17) —
Nausea 7 (23) 8 (27) 3 (10) —
Vomiting 5 (17) 7 (23) 2 (7) —
Mucositis 7 (23) 3 (10) — —
Alopecia 7 (23) 8 (27) — —
Anorexia 5 (17) 6 (20) 3 (10) —
Skin toxicity 4 (13) 1 (3) 2 (7) —
Ataxia — 1 (3) 1 (3) —
Neuropathy 2 (7) — — —
Abdominal pain 5 (17) 1 (3) — —
Dyspepsia 4 (13) — — —
Constipation 3 (10) — — —
Fever 1 (3) 1 (3) — —
Infection 1 (3) — — —
Cholinergic 3 (10) — — —
Raised bilirubin — — 1 (3) —
Hiccoughs — — 1 (3) —
Other 6 (20) 3 (10) — —
Table 5 Worst toxicity experienced (n¼30)
Worst toxicity grade Number of patients (%)
0 4 (13)
1 1 (3)
2 13 (43)
3 12 (40)
4 1 (3)
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seventually having a dose reduction or withdrawal during the first
six cycles. The most common toxicities were, once again, lethargy,
diarrhoea, nausea and anorexia occurring at any grade in 77, 67, 59
and 45% of patients, respectively and reaching grade X3 in 19, 16,
10 and 10%, respectively. Although in this patient population
such symptoms may have been only partly caused by
the chemotherapy drugs, in many patients, they were cyclical in
nature and it was felt that therapy was a significant contri-
butor. There were no episodes of febrile neutropenia, and grade
42 HFS occurred in only two (6%) patients. We noted three
acute venous events during treatment, although none were
reported by the clinicians as treatment related. A possible
explanation for the greater toxicity seen for dose level 3 in phase
II is that the intra-patient dose escalation utilised during phase I
introduced selection bias (patients tolerating lower dose levels are
more likely to tolerate higher dose levels than treatment-naı ¨ve
patients) and consequently underestimated the toxicity of dose
level 3.
Published phase II studies of the irinotecan/capecitabine
combination in colorectal cancer have reported similar frequencies
and types of grade X3 toxicity, with diarrhoea being the
commonest, occurring in around 20% of patients and grade X3
neutropenia, lethargy, nausea and anorexia in around 10–20%
(Bajetta et al, 2004; Borner et al, 2005). Recently, the EORTC 40015
phase III study, comparing 2-weekly irinotecan/LV5FU2 vs
3-weekly irinotecan/capecitabine (both arms7celecoxib) in
advanced colorectal cancer, was stopped prematurely because of
excessive toxicity (Kohne et al, 2005). In that study, there was
significantly more grade X3 diarrhoea with irinotecan/capecita-
bine (31%) than with irinotecan/LV5FU2 (6.9%); in addition,
deaths felt to be caused or exacerbated by treatment occurred in
five of 44 (11%) patients on irinotecan/capecitabine, most
commonly with diarrhoea, sepsis and/or thrombotic events. The
investigators concluded that the doses used (irinotecan
250mgm
 2; capecitabine 1000mgm
 2 b.d. on days 1–14 every 3
weeks) were not feasible in their study.
Our 2-weekly regimen is active in advanced gastroesophageal
adenocarcinoma in the first-line setting. In the phase II cohort, the
objective response rate was 32%, and an additional 14% patients
with stable disease by RECIST criteria nonetheless experienced
symptomatic improvement together with improvement in CT scan
appearances and/or serum markers. Although similar to the
reported results of standard ECF or other irinotecan-based
regimens, comparison is of course not possible in this non-
randomised study.
We used a single (weeks 13–14) time point at which to assess
response. This may have underestimated the response rate
compared with a method using serial imaging to assess the best
response obtained. However, in our experience, the vast majority
of patients with responsive gastroesophageal adenocarcinoma will
have responded following 3 months of effective therapy.
In colorectal cancer, it has been shown that, when combined
with 2-weekly oxaliplatin, administered dose intensity of capeci-
tabine can be increased without additional toxicity when compared
to the standard 3-weekly schedule. This was achieved by
administering the fluoropyrimidine at higher dose for 7 days
during each 14-day cycle. Additionally, this regimen was
associated with increased response rates and time to progression
(Scheithauer et al, 2003). It is conceivable that, by adopting a
similar schedule in combination with 2-weekly irinotecan, the
efficacy of our regimen could be improved. However, it is quite
possible that the toxicity of this dose-intensive regimen in
combination with irinotecan, in patients with gastroesophageal
cancer, would be prohibitive.
Recently, a phase II trial of a 3-weekly regimen of irinotecan/
capecitabine in advanced gastroesophageal carcinoma was pre-
sented in abstract form (Assersohn et al, 2005). This regimen was
administered to 25 eligible patients who had all progressed
through, or relapsed within 3 months of, platinum-based
chemotherapy. Of the 21 assessable patients, three (14%)
responded and a further three (14%) had stable disease. An
improvement in a variety of tumour-related symptoms was also
noted. Only one patient (4%) developed febrile neutropenia and
there were no toxic deaths, but further toxicity data are yet to be
reported.
Irinotecan combined with infusional FU/LV has been studied in
two recent randomised phase II studies. In the first, this
combination, given using a weekly schedule, appeared to provide
superior efficacy to irinotecan/cisplatin, but with a high rate (27%)
of grade X3 diarrhoea (Pozzo et al, 2004). In the second, the
fortnightly irinotecan/FU/LV regimen was compared to FU/LV
alone and FU/LV/cisplatin: it produced better rates of response
and progression-free survival than either comparator (Bouche ´
et al, 2004). The response rate and median overall survival seen
with irinotecan/FU/LV in these two studies was 42%, 10.7 months
and 40%, 11.3 months, respectively, consistent with our findings
for irinotecan/capecitabine. Most recently, a phase III trial
comparing irinotecan/FU with cisplatin/FU has been presented
in abstract form: there was a non-statistically significant trend
towards improved time to progression in the irinotecan arm but
there was no difference in overall survival; patients randomised to
irinotecan/FU experienced less febrile neutropenia, nausea and
stomatitis but more diarrhoea than those randomised to cisplatin/
FU (Dank et al, 2005).
Based on the data presented to date, it appears that irinotecan-
based regimens represent a treatment option for the treatment
of gastroesophageal cancer, but are not a major therapeutic
advance over standard cisplatin-based regimens. They seem to
have similar efficacy, and represent a useful option, especially for
patients at risk of cisplatin toxicities. They may also represent a
treatment option in the second-line setting following failure of
cisplatin, but ideally this should be tested in a randomised trial
against best supportive care. It is uncertain at this stage if
capecitabine can be substituted for FU without compromising
efficacy and safety when used in combination with irinotecan; our
experience would suggest that this is feasible, but the safety results
of EORTC 40015 in advanced colorectal cancer are a cause for
concern.
In conclusion, our study suggests that the fortnightly regimen of
irinotecan 180mgm
 2 on day 1 together with capecitabine
1000mgm
 2 on days 1–9 is an active regimen in advanced
gastroesophageal adenocarcinoma, but requires modification in
order to improve its toxicity profile. In the MRC FOCUS trial in
advanced colorectal cancer, this regimen – but with a reduced
capecitabine dose of 800mgm
 2 b.d. on days 1–9 – was used as
second/third-line crossover treatment after FU/LV and oxaliplatin
(Seymour, 2005). To date, it appears to be active and well tolerated
in that context, but full reporting of that trial is awaited.
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